Filing Details
Eikon Therapeutics, Inc. (NASDAQ:EIKN) filed a Form 8-K with the Securities and Exchange Commission on October 23, 2026, disclosing a material event.
8k filedNASDAQ:EIKN
Eikon Therapeutics, Inc. (EIKN) Reports Material Event to SEC
Eikon Therapeutics, Inc. (NASDAQ:EIKN) filed a Form 8-K with the Securities and Exchange Commission on October 23, 2026, disclosing a material event.
At publication ·
What changed
Eikon Therapeutics, Inc. (NASDAQ:EIKN) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Eikon Therapeutics filed a Form 8-K on October 23, 2026, disclosing a material event that shareholders should know about.
- The company's stock was trading at $7.26 at the time of the disclosure.
- Form 8-K filings report material events such as leadership changes, agreements, acquisitions, asset sales, or financial guidance changes.
Market Context
Eikon Therapeutics, Inc.'s stock currently trades at $7.26. The company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Eikon Therapeutics, Inc.'s stock.
All SEC filings for Eikon Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View EIKN Stock Page
Frequently Asked Questions
Where can I read EIKN's SEC filings?
Browse all filings on our EIKN SEC filings page.
What types of SEC filings does Eikon Therapeutics, Inc. file?
Public companies like Eikon Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.